LDL Cholesterol

15 registered clinical trials studyying LDL Cholesterol — 5 currently recruiting.

Status	Trial	Sponsor	Phase
Recruiting	Effects of Milk-based Drinks on Gut Microbiome, Sleep and Cardiometabolic Markers NCT07071181	Sheffield Hallam University	N/A
Not Yet Recruiting	Efficacy of Lipid-Lowering Therapy Based on Apolipoprotein B Versus LDL-Cholesterol Levels in Patients Undergo NCT06626126	University Medical Center Ho Chi Minh City (UMC)	N/A
Enrolling By Invitation	A Study on Evaluating the Safety of HST101 in Healthy Chinese Participants NCT06504043	Hasten Biopharmaceutical Co., Ltd.	Phase 1
Not Yet Recruiting	Intensive Lipid-lowering in Patients With STEMI and NSTEMI (Germany on Target) NCT05587621	Jena University Hospital	N/A
Recruiting	LDL Cholesterol TARGETs in OLDer Patients (Age≥75 Years) With ASCVD (TARGET OLD) NCT05765370	China National Center for Cardiovascular Diseases	N/A
Completed	Cardiovascular Risk Prevention With a Mediterranean Dietary Pattern Reduced in Saturated Fat NCT05778656	Universidad de Granada	N/A
Completed	Evaluation of a Probiotic on LDL-cholesterol Levels NCT04029818	Biosearch S.A.	Phase 1
Completed	Study to Evaluate Efficacy and Safety of LIB003 in Patients on Lipid-Lowering Therapy Needing Additional LDL-C NCT03549260	LIB Therapeutics LLC	Phase 2
Completed	Dietary Intervention With Brain-friendly Diet NCT03346486	Fazer Group	N/A
Completed	Randomized Evaluation of Anagliptin Versus Sitagliptin On Low-density lipoproteiN Cholesterol in Diabetes Tria NCT02330406	Institute for Clinical Effectiveness, Japan	Phase 4
Unknown	Effect of Viscous Soluble Fibers on Serum Cholesterol Levels NCT02068248	Unity Health Toronto	—
Completed	Safety, Pharmacokinetics and Pharmacodynamics of LGT209 in Healthy Volunteers With Elevated Cholesterol and in NCT01859455	Novartis Pharmaceuticals	Phase 1
Completed	Safety and Efficacy of a Natural Health Product in Reducing Cholesterol and Triglyceride Levels. NCT01028274	Nordic Pharma, USA	Phase 1 / Phase 2
Completed	DIALOOG: Crestor in Patients With Diabetes Mellitus Type 2: Lowering of LDL-C Levels to New European Guideline NCT00233649	AstraZeneca	—
Completed	Effects of Achieving Very Low LDL-Cholesterol After Treatment With Statins on Steroidogenesis and Cognition NCT00522158	Baskent University	Phase 4